Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 535 of 5804
-
New drug cocktails aim to shrink Hard-to-Treat gut cancers
Disease control Recruiting nowThe purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subpro…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for hodgkin lymphoma patients unable to tolerate chemo
Disease control Recruiting nowThis is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Hand vs. wrist: which route to the heart is safer during a heart attack?
Disease control CompletedRecently, a novel distal transradial, through anatomical snuffbox, approach has been proposed for undertaking percutaneous coronary angiography and interventions. The existing literature has evaluated distal transradial access (dTRA) as a feasible and safe approach, with faster h…
Phase: NA • Sponsor: University Hospital of Patras • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedThe investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patient…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New mRNA flu shot shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as har…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:06 UTC
-
HIV kidney transplants: can donor choice reduce rejection?
Disease control Recruiting nowThis research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New program aims to boost HIV viral suppression in latino community
Disease control Recruiting nowThe goal of this study is to test the effectiveness of ADELANTE on viral suppression among Latinos with HIV and viral non-suppression. Participants will receive ADELANTE (5-session, community health worker-delivered, problem-solving intervention) or enhanced care condition (ECC, …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New targeted pill shows promise for tough lung cancer
Disease control Recruiting nowA first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell …
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Dialysis heart risk: which beta blocker wins?
Disease control Recruiting nowThe investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized t…
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for brain cancer patients: drug combo targets aggressive tumors
Disease control OngoingThe trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may spot lung cancer early, avoiding unnecessary biopsies
Diagnosis Recruiting nowThe goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biom…
Sponsor: Herlev and Gentofte Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Aspirin's hidden power against a dangerous pregnancy complication revealed
Prevention ENROLLING_BY_INVITATIONPrimary outcome 1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF) 2. to identify biological effects of aspirin in nulliparous women with high risk for preeclampsia Secondary outc…
Sponsor: Norwegian University of Science and Technology • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Food flavors on the breath may reveal hidden liver disease
Diagnosis CompletedThe Early Liver Disease Breath Detection Study is a cross-sectional study where subjects with advanced liver fibrosis will ingest a mixture of food-grade compounds (known as Exogenous Volatile Organic Compound or EVOCs) in the form of an emulsion and then provide multiple breath …
Sponsor: Owlstone Ltd • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
New hope for Hard-to-Treat merkel cell cancer: drug combo trial underway
Disease control OngoingThis phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (re…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug may boost recovery in kids with rare bone marrow failure
Disease control Recruiting nowThe purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug duo aims to slow rare spleen cancer
Disease control OngoingThe goal of this clinical trial is to compare the efficacy and tolerability of the combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab monotherapy in patients with Splenic Marginal Zone Lymphoma (SMZL), previously untreated and who need syste…
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New shot every 3 months could tame high blood fats
Disease control OngoingThis Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or …
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Lighter anesthesia may shield seniors from Post-Surgery confusion
Disease control Recruiting nowThe goal of this clinical trial (Balanced-2 study) is to compare light to deep general anesthesia using widely available brain monitors, to see if 'light' anesthesia could reduce rates of delirium, cognitive decline, and disability in older adults undergoing major surgery. Delir…
Phase: NA • Sponsor: Auckland City Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC